TY - JOUR
T1 - Serum Neurofilament Light Chain in Multiple Sclerosis
T2 - Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response
AU - Swiss Multiple Sclerosis Cohort Study (SMSC)
AU - Einsiedler, Maximilian
AU - Maceski, Aleksandra Maleska
AU - Sandgren, Sofia
AU - Oechtering, Johanna
AU - Schaedelin, Sabine
AU - Hofer, Lisa
AU - Zadic, Amar
AU - Gomez, Juan Francisco Vilchez
AU - Melie-Garcia, Lester
AU - Cagol, Alessandro
AU - Galbusera, Riccardo
AU - Finkener, Sebastian
AU - Lalive, Patrice
AU - Uginet, Marjolaine
AU - Müller, Stefanie
AU - Pot, Caroline
AU - Mathias, Amandine
AU - Du Pasquier, Renaud
AU - Hoepner, Robert
AU - Chan, Andrew
AU - Disanto, Giulio
AU - Zecca, Chiara
AU - D’Souza, Marcus
AU - Hemkens, Lars G.
AU - Derfuss, Tobias
AU - Yaldizli, Özgür
AU - Roth, Patrick
AU - Gobbi, Claudio
AU - Brassat, David
AU - Tackenberg, Björn
AU - Zetterberg, Henrik
AU - Ziemssen, Tjalf
AU - Wiendl, Heinz
AU - Berger, Klaus
AU - Hermesdorf, Marco
AU - Piehl, Fredrik
AU - Kappos, Ludwig
AU - Granziera, Cristina
AU - Abdelhak, Ahmed
AU - Leppert, David
AU - Willemse, Eline A.J.
AU - Benkert, Pascal
AU - Kuhle, Jens
N1 - Publisher Copyright:
© 2025 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
PY - 2025/11
Y1 - 2025/11
N2 - Objective: Prognostication of disease course and prediction of treatment response in multiple sclerosis is an unmet need. We compared the performance of serum neurofilament light chain Z scores (age- and BMI-adjusted) with absolute concentrations for the prediction of response to disease-modifying therapy. Methods: Observational cohort study including the first serum sample of participants after the start of fingolimod therapy. We estimated hazard ratios for future relapses comparing participants with high (upper quartile) versus lower neurofilament light chain levels, based on either absolute concentration or Z score cutoffs. We compared the prognostic/predictive performance of these two measures for the occurrence of new/enlarging T2w lesions in longitudinal MRI. Results: We included 447 participants (median [IQR] age, 41.3 [32.1–49.2] years; 65.1% female); median follow-up 8.3 years [6.0–10.3]. Participants with a high neurofilament light chain Z score (Z ≥ 1.2/88.5 percentile) were more likely to experience future relapses (HR: 1.80, 95% CI 1.27–2.54, p < 0.001) compared to those below this threshold while this dichotomy could not be demonstrated with absolute concentration cutoffs (≥ vs. < 10.8 pg/mL; HR: 0.94, 95% CI 0.64–1.38, p = 0.75). Furthermore, patients with upper quartile Z scores were associated with a higher incidence of new/enlarging T2w lesions compared with those below this threshold (OR: 1.88, 95% CI 1.31–2.70, p < 0.001); again, absolute concentration cutoffs failed to identify this risk (OR: 1.20, 95% CI 0.82–1.77, p = 0.34). These findings were confirmed when patients having started alternative oral treatments were also included (n = 713). Interpretation: Serum neurofilament light chain Z scores consistently outperformed absolute concentration cutoffs for prognostication of clinical/radiological disease activity and may facilitate individual prediction of treatment response.
AB - Objective: Prognostication of disease course and prediction of treatment response in multiple sclerosis is an unmet need. We compared the performance of serum neurofilament light chain Z scores (age- and BMI-adjusted) with absolute concentrations for the prediction of response to disease-modifying therapy. Methods: Observational cohort study including the first serum sample of participants after the start of fingolimod therapy. We estimated hazard ratios for future relapses comparing participants with high (upper quartile) versus lower neurofilament light chain levels, based on either absolute concentration or Z score cutoffs. We compared the prognostic/predictive performance of these two measures for the occurrence of new/enlarging T2w lesions in longitudinal MRI. Results: We included 447 participants (median [IQR] age, 41.3 [32.1–49.2] years; 65.1% female); median follow-up 8.3 years [6.0–10.3]. Participants with a high neurofilament light chain Z score (Z ≥ 1.2/88.5 percentile) were more likely to experience future relapses (HR: 1.80, 95% CI 1.27–2.54, p < 0.001) compared to those below this threshold while this dichotomy could not be demonstrated with absolute concentration cutoffs (≥ vs. < 10.8 pg/mL; HR: 0.94, 95% CI 0.64–1.38, p = 0.75). Furthermore, patients with upper quartile Z scores were associated with a higher incidence of new/enlarging T2w lesions compared with those below this threshold (OR: 1.88, 95% CI 1.31–2.70, p < 0.001); again, absolute concentration cutoffs failed to identify this risk (OR: 1.20, 95% CI 0.82–1.77, p = 0.34). These findings were confirmed when patients having started alternative oral treatments were also included (n = 713). Interpretation: Serum neurofilament light chain Z scores consistently outperformed absolute concentration cutoffs for prognostication of clinical/radiological disease activity and may facilitate individual prediction of treatment response.
KW - Z scores
KW - multiple sclerosis
KW - neurofilament
KW - prediction
UR - https://www.scopus.com/pages/publications/105013768753
U2 - 10.1002/acn3.70149
DO - 10.1002/acn3.70149
M3 - Article
C2 - 40755082
AN - SCOPUS:105013768753
SN - 2328-9503
VL - 12
SP - 2214
EP - 2225
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 11
ER -